J&J slides after jury orders it to pay $8 billion in male breast-growth case (JNJ)

A Philadelphia jury ruled Johnson & Johnson must pay $8 billion in damages to a man claiming the company didn't properly warn male consumers its Risperdal drug could prompt breast growth. The company's stock fell as much as 1.5% on Wednesday following the Tuesday decision. The case, brought by Nicholas Murray, is one of 13,400 Risperdal-related lawsuits, according to J&J's latest SEC filings. Watch J&J trade live here. A Philadelphia jury ordered Johnson & Johnson to pay $8 billion in...